10-Q: Quarterly report

SEC announcementJun 25 12:27 ET · Announcements

Akari Therapeutics Sees Cost Savings Through Reduced Clinical Trial, Infrastructure Costs >AKTX

Akari Therapeutics Sees Cost Savings Through Reduced Clinical Trial, Infrastructure Costs >AKTX

Dow JonesMay 1 08:10 ET

Press Release: Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics

Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanc

Dow JonesMay 1 08:01 ET

Press Release: Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity

Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity -- Prioritization of Peak's ADC cancer therapeutic platform technology and Akari'

Dow JonesMay 1 08:01 ET

Peak Bio's Strategic Merger With Akari Therapeutics

TipRanksMar 5 17:03 ET

Shareholder Alert: Ademi LLP Investigates Whether Peak Bio Inc. Has Obtained a Fair Price in Its Transaction With Akari

MILWAUKEE, March 5, 2024 /PRNewswire/ -- Ademi LLP is investigating Peak Bio (OTC: PKBO) for possible breaches of fiduciary duty and other violations of law in its transaction with Akari. Click here

PR NewswireMar 5 12:27 ET